8-K: Phibro Animal Health to Acquire Zoetis' Medicated Feed Additive Portfolio for $350 Million

Phibro Animal Health has agreed to acquire Zoetis' medicated feed additive portfolio, certain water soluble products, and related assets for $350 million, significantly expanding its product offerings and global reach.

Summary

• Phibro Animal Health Corporation will acquire Zoetis' medicated feed additive (MFA) product portfolio, certain water soluble products, and related assets for $350 million.
• The acquisition includes the purchase of equity interests in Zoetis Medolla Manufacturing S.r.l. and Zoetis Suzhou Manufacturing Co., Ltd., as well as other assets.
• The acquired portfolio generated approximately $400 million in revenue in 2023 and includes over 37 product lines sold in about 80 countries.
• Six manufacturing sites, four in the U.S., one in Italy, and one in China, are part of the deal.
• Over 300 Zoetis employees supporting manufacturing, distribution, and commercial activities are expected to transition to Phibro.
• Phibro plans to finance the transaction with approximately $325 million in new debt and balance sheet cash.
• The deal is expected to close in the second half of calendar year 2024, subject to regulatory approvals and other customary closing conditions.
• Phibro expects to have net leverage of 3.5-4.0x Debt / Adjusted EBITDA at close, targeting below 3.0x by its fiscal year end June 30, 2027.
• The combined sales for Phibro Animal Health, including the acquired portfolio, would have been approximately $1.4 billion in the last twelve months.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook with a strategic acquisition that is expected to be accretive to earnings and expand Phibro's market presence. The financing is secured, and the management commentary is optimistic.

Positives

• The acquisition will significantly expand Phibro's product portfolio and global reach.
• The acquired portfolio is expected to boost Phibro's profitability and EBITDA margin.
• The transaction is expected to be accretive to Phibro's Adjusted Earnings Per Share.
• The acquisition will diversify Phibro's portfolio across species and products.
• Phibro's cash generation is expected to allow for continued investment into higher growth businesses.
• The deal includes a large number of product lines and manufacturing sites, providing immediate scale.

Negatives

• Phibro will take on approximately $325 million in new debt to finance the acquisition.
• The transaction is subject to customary closing conditions, including regulatory approvals, which could delay or prevent the deal from closing.
• Integrating the acquired business and employees could present challenges.

Risks

• The transaction is subject to regulatory approvals, which may not be obtained or could delay the closing.
• The financing for the acquisition may not be obtained on the expected terms or at all.
• The expected benefits of the transaction may not be fully realized or may take longer than expected.
• The integration of the acquired business may be more difficult, time-consuming, or costly than anticipated.
• There is a risk of diversion of management's attention during the integration process.
• The transaction could impact relationships with customers, governmental authorities, suppliers, employees, and other business counterparties.

Future Outlook

The acquisition is expected to boost Phibro's profitability and EBITDA margin and be accretive to its Adjusted Earnings Per Share. Phibro aims to reduce its net leverage to below 3.0x by its fiscal year end June 30, 2027.

Management Comments

• Kristin Peck, Chief Executive Officer of Zoetis, stated that the long-term value of the transferred portfolio will be fully realized with Phibro Animal Health.
• Jack C. Bendheim, Chairman, President and Chief Executive Officer of Phibro Animal Health, said that this investment will enhance, diversify, and broaden their portfolio globally.
• Jack C. Bendheim also mentioned that Phibro's cash generation will allow for continued investment into higher growth businesses.

Industry Context

This acquisition reflects a trend of consolidation in the animal health industry, with companies focusing on core competencies and divesting non-core assets. Zoetis is focusing on vaccines, biologics, and genetics, while Phibro is expanding its presence in the medicated feed additive market.

Comparison to Industry Standards

• The acquisition of a $400 million revenue portfolio for $350 million is within the typical range for similar transactions in the animal health sector.
• Zoetis, a Fortune 500 company with $8.5 billion in revenue in 2023, is divesting a non-core asset to focus on its strategic priorities, similar to other large players in the industry.
• Phibro's target leverage ratio of below 3.0x by 2027 is a common goal for companies looking to maintain a healthy balance sheet after a significant acquisition.
• Other companies such as Elanco and Boehringer Ingelheim have also made strategic acquisitions and divestitures to optimize their portfolios.

Stakeholder Impact

• Shareholders of Phibro are expected to benefit from the increased revenue and profitability.
• Employees of Zoetis who are transitioning to Phibro will experience a change in employer.
• Customers of both Zoetis and Phibro will experience a transition in product supply and support.
• Suppliers of both companies may see changes in their business relationships.

Next Steps

• Phibro will file the Purchase Agreement and Commitment Letter as exhibits to its Annual Report on Form 10-K.
• Phibro will work to obtain regulatory approvals for the transaction.
• Phibro will finalize the definitive documentation for the Incremental Term Facility.
• Phibro will integrate the acquired business and employees.
• Phibro will host an investor call on April 29 to discuss the acquisition.

Key Dates

Keywords

acquisition, medicated feed additive, animal health, Zoetis, Phibro, MFA, debt financing, manufacturing, portfolio, EBITDA